Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30826998 | 0.89 | PDE5A (0.39) | PDE5APLCG1CYP11B1ALDH1A1CTSS | |
| SCHEMBL22551784 | 0.81 | USP8 (0.43) | ARPLCG1CYP11B1ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL7429009 | 0.81 | KDM4E (0.53) | PLCG1CYP11B1KDM4EMAPK1 | |
| SCHEMBL11498598 | 0.80 | PDE5A (0.45) | PDE5APLCG1ALDH1A1CYP19A1KDM4E | |
| SCHEMBL22552118 | 0.79 | HTR7 (0.49) | ALDH1A1KDM4E | |
| SCHEMBL27858859 | 0.79 | CYP11B1 (0.40) | PLCG1CYP11B1 | |
| SCHEMBL28263826 | 0.79 | CYP11B1 (0.40) | PLCG1CYP11B1 | |
| SCHEMBL1061776 | 0.79 | CYP11B1 (0.40) | PDE5APLCG1CYP11B1ALDH1A1CYP11B2 | |
| SCHEMBL10221817 | 0.79 | PKM (0.49) | PDE5APLCG1CYP11B1ALDH1A1 | |
| SCHEMBL4282591 | 0.77 | L3MBTL1 (0.47) | PLCG1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| CN-115181092-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-112279837-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PDE5A 129/4885AR 7/4885PLCG1 193/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PDE5A 129/4885AR 7/4885PLCG1 193/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PDE5A 129/4885AR 7/4885PLCG1 193/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PDE5A 129/4885AR 7/4885PLCG1 193/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PDE5A 129/4885AR 7/4885PLCG1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.